BioHarvest Sciences

BHST

Market cap $108M

BioHarvest Sciences Inc (NASDAQ:BHST) said its first full year as a Nasdaq-listed company was marked by revenue growth, expanding operations, and balance sheet improvements, according to a shareholder letter released on Wednesday by CEO Ilan Sobel. In the letter, Sobel outlined operating and financial progress made in 2025 and described the company's position entering 2026.

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 7, 2026) - BioHarvest Sciences Inc. , (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today issued a letter to shareholder partners from Chief Executive Officer, Ilan Sobel. Dear Fellow Shareholders, 2025 marked an important milestone for BioHarvest Sciences: our first full year as a NASDAQ-listed company, and we enter 2026 with an annualized revenue run rate exceeding US$36 million and gross margins above 60%.

BioHarvest Sciences Inc (NASDAQ:BHST) said on Thursday it has been awarded a $1.6 million grant from the Israeli Innovation Authority (IIA) to support the development of its second-generation Botanical Synthesis manufacturing process. The biotechnology company said the funding was approved under the IIA's Bio-Convergence program, which backs technologies combining biology, engineering, data science and artificial intelligence.

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - December 18, 2025) - BioHarvest Sciences Inc . (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ platform, today announced that it has been awarded a $1.6 million grant from the Israeli Innovation Authority (IIA).

BioHarvest Sciences Inc. (NASDAQ:BHST) has launched VINIA Blood Hydration, a new electrolyte product that incorporates the company's Piceid resveratrol ingredient. The launch marks BioHarvest's entry into the US hydration and electrolyte category, a market the company cites as worth about $13 billion.

First Hydration Formula Powered by VINIA's Blood Flow Technology Enters the $13 Billion U.S. Electrolyte Market Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - December 3, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the U.S. launch of VINIA Blood Flow Hydration™, the first hydration solution powered by the blood flow benefits of VINIA's Piceid resveratrol to enter the $13 Billion US Electrolytes Drink Market*. Better Hydration Starts with Better Blood Flow Following overwhelmingly positive early-adopter interest, VINIA Blood Flow Hydration™ is now shipping nationwide and is available exclusively at Vinia.com, with free delivery across North America.

BioHarvest Sciences Inc. ( BHST ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Ilan Sobel - Chief Executive Officer Bar Dichter - Chief Financial Officer Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Nicholas Sherwood - Maxim Group LLC, Research Division Susan Anderson - Canaccord Genuity Corp., Research Division Presentation Operator Greetings, and welcome to the BioHarvest Sciences Third Quarter 2025 Corporate Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago.

BioHarvest Sciences Inc. (NASDAQ:BHST), a biotechnology company known for its patented Botanical Synthesis technology, reported a 39% increase in third-quarter revenue, driven by growth in its core VINIA capsule business and expanding contract development and manufacturing (CDMO) operations. Total revenues for the quarter ended September 30 rose to $9.1 million, in line with management guidance.

Strong VINIA Momentum and New CDMO Win Delivers 39% Year-Over-Year Growth Company Fortifies Balance Sheet with Recent $19.9 Million Instiutional Equity Raise Following $14.7 Million Strengthening of Balance Sheet via Accelerated Warrant Exercises and Debt-to-Equity Conversions in September Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 13, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the third quarter ended September 30, 2025. Third Quarter 2025 Operational Highlights All figures stated in this news release are in U.S. dollars unless stated otherwise.